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Abstract: Extremely multiresistant strains of Enterobacteriaceae are emerging and spreading at a
worrisome pace. Polymyxins are used as the last-resort therapy against such strains, in spite of
their nephrotoxicity. We have previously shown that novel polymyxin derivatives NAB739 and
NAB815 are less nephrotoxic in cynomolgus monkeys than polymyxin B and are therapeutic in
murine Escherichia coli pyelonephritis at doses only one-tenth of that needed for polymyxin B. Here
we evaluated whether the increased efficacy is due to increased excretion of NAB739 in urine. Mice
were treated with NAB739 and polymyxin B four times subcutaneously at doses of 0.25, 0.5, 1, 2,
and 4 mg/kg. In plasma, a clear dose–response relationship was observed. The linearity of Cmax
with the dose was 0.9987 for NAB739 and 0.975 for polymyxin B. After administration of NAB739
at a dose of 0.25 mg/kg, its plasma concentrations at all tested time points were above 0.5 µg/mL
while after administration at a dose of 0.5 mg/kg its plasma concentrations exceeded 1 µg/mL. The
Cmax of NAB739 in plasma was up to 1.5-times higher after single (first) administration and up to
two-times higher after the last administration when compared to polymyxin B. Polymyxin B was
not detected in urine samples even when administered at 4 mg/kg. In contrast, the concentration of
NAB739 in urine after single administration at a dose of 0.25 mg/kg was above 1 µg/mL and after
administration of 0.5 mg/kg its average urine concentration exceeded 2 µg/mL. At the NAB739 dose
of 4 mg/kg, the urinary concentrations were higher than 35 µg/mL. These differences explain our
previous finding that NAB739 is much more efficacious than polymyxin B in the therapy of murine E.
coli pyelonephritis.
Keywords: NAB739; polymyxin B; mouse pyelonephritis; extremely multiresistant strains
of Enterobacteriaceae
1. Introduction
Extremely multiresistant strains of Enterobacteriaceae, such as those of Escherichia coli and Klebsiella
pneumoniae, are emerging and spreading at a worrisome pace. In the last few years also the species
Proteus mirabilis has emerged as a frequent and important cause of the onset of urinary tract infections
(UTIs) [1,2]. Two polymyxin class antibiotics, colistin and polymyxin B (PMB), are currently used as the
last-resort therapy against multidrug resistant strains, in spite of their nephrotoxicity. Unfortunately,
polymyxins are highly nephrotoxic agents which frequently induce acute kidney injury at conventional
doses and may require discontinuation of the therapy [3]. Quite recently, international consensus
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guidelines have been published on the optimal use of polymyxins [3]. Numerous efforts have been
made to develop derivatives of polymyxins that are less nephrotoxic than those now in clinical use.
Another approach is designing of new polymyxin derivatives that are more effective than the old ones
and therefore could be used at lower, better tolerated doses. An excellent and comprehensive review
on those attempts has recently been published [4].
Polymyxins are cyclic lipopeptides that have a cyclic heptapeptide part and a linear tripeptide
part, linked to a fatty acyl moiety. Colistin and PMB are highly charged because of five free positively
charged amino groups, three of them in the cyclic part and two in the linear part of the molecule.
Depending on localization of cationic functional groups, both efficacy and nephrotoxicity of polymyxins
is due to the highly cationic nature of the molecule [5]. We have synthesized polymyxin derivatives
that carry only three positive charges (Figure 1) [6,7]. NAB739 does not carry any positive charge in
the linear peptide part. NAB815 carries only one positive charge in the linear part and two positive
charges in the cyclic part. In cynomolgus monkeys both novel polymyxins are less nephrotoxic than
PMB. In addition, unlike PMB, both NAB compounds are excreted in the cynomolgus urine at a very
significant extent [6,7]. Additionally, in patients, only less than 1% of PMB dose is excreted in urine
which significantly limits their use for the treatment of urinary tract infections [8].
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Figure 1. The structure of polymyxin B2 and NAB739. Polymyxin B2-specific functional groups are
indicated with red font. Stars outline charged –NH2 groups.
In a muri e model of E. coli pyelonephritis, both NAB739 and NAB815 reduced the bacterial
burden in the kidney, urine, and bladder at doses approximately 10-fold lower than those of PMB [9].
In kidn ys, the half maximal effective dose (ED50) was 0.24 mg/kg for NAB739 and 2.1 mg/kg for PMB.
We hypothesized that the substantially increased efficacy might be related to increased urinary levels
of new polymyxins. Therefore, we studied the comparative urinary levels of NAB739 and PMB in mice
using various doses to show that sufficient-for-efficacy amounts of NAB739 are excreted in the urine
whereas PMB is not present in the murine urine even after the treatment at the highest dose of 4 mg/kg.
2. Materials and Methods
2.1. Methods
NAB739 sulfate was custom-made by Bachem AG (Bubendorf, Switzerland). Its purity, as
estimated by HPLC, was 97.3%. Polymyxin B (PMB) sulfate was from Sigma-Aldrich (St. Louis,
MO, USA; product number PO0972). Sterile sodium chloride 0.9% solution was obtained from
Fresenius Kabi (Bad Homburg, Germany). Microvette for capillary blood collection was from Sarstedt
(Nümbrecht, Germany). Hydrophobic sand LabSand for urine sample collection was from Datesand
Group (Manchester, UK).
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2.2. Animals
NMRI female mice (10–12 weeks old, 29–32 g, n = 64) were obtained from ENVIGO (The
Netherlands) and housed prior to treatment under standard conditions (acclimatization period of 1
week, 21–23 ◦C, 12-h light/dark cycle, relative humidity 45%–65%) with unlimited access to food (R70
diet from Lantmännen) and water. The experimental procedures were performed in accordance with
the guidelines of the European Community and local laws and policies (Directive 2010/63/EU), and
all of the procedures were approved by Food and Veterinary Service, Riga, Latvia. Studies involving
animals are reported in accordance with the ARRIVE guidelines [10,11]. Animals were weighed on
the day of the treatment (before treatment) to calculate the required amount of compound for the
corresponding dose. For PK and excretion studies the mice were dosed subcutaneously (SC) via a
bolus injection (injection volume 10 mL/kg). Four consecutive doses were administrated twice a day at
9:00 AM and 15:00 PM over the course of two days.
Blood samples were collected in tubes containing heparin. Blood was sampled from tail vein 15,
30, and 45 min after the first and last administrations of the compounds. Tubes were centrifuged at
+4 ◦C 10,000× g for 3 min. Plasma samples were collected and stored at −20 ◦C until analysis.
For PK study, before the administration of the compound, mice voiding was stimulated. Then
compound was administrated SC. Mice were put in separate cages with LabSand (USA) and urine was
collected during the next 3 h. At the end of each 1-h period voiding was stimulated by gentle massage
of the belly. Urine samples from each mouse were pooled in one tube. Urine volume was determined
by weighing of the pooled urine sample.
2.3. Plasma and Urine Sample Analysis
Plasma and urine sample analyses were performed using the quantitative UPLC/MS/MS method.
Calibration standards and quality control samples for plasma analysis were prepared by spiking blank
mouse plasma (CD-1, anticoagulant Na Heparin, Innovative Research, USA) with a stock solution
of analyte to achieve a nominal concentration ranging from 0.01 to 50 µg/mL for NAB739 and PMB.
Calibration standards and quality control samples for urine analysis were prepared by spiking blank
mouse urine (mouse CD-1 urine, Sera Laboratories International Ltd., UK) with a stock solution of
analytes to achieve a nominal concentration from 0.04 to 30 µg/mL for NAB739 and PMB.
A sample volume of 20 µL (calibration standards, quality controls or analytical samples in plasma
or urine) was transferred into the plastic tube and mixed with 100 µL of 1% formic acid solution in
acetonitrile/methanol (3:1, v/v) mixture to precipitate proteins. The tubes were vortex- mixed and
centrifuged at 10,000 rpm for 10 min. Then, 100 µL of supernatant was diluted with 400 µL of water
and subjected to UPLC/MS analysis as follows:
UPLC system Acquity H-class (Waters) connected with triple quadrupole mass spectrometer
Xevo TQ-S (Waters). UPLC conditions: Column—Acquity BEH C18 (2.1 × 50 mm, 1.7 µm); Mobile
phase—A: 0.1% Formic acid aqueous solution, B: Acetonitrile; Gradient: Initial—90%A, 2.5 min—5%
A, 4.0 min—5% A, 4.5 min—90% A, 6 min—90% A; Flow—0.3 mL/min; Column temperature—40 ◦C;
Injection volume—1 µL (NAB739) or 5 µL (PMB). MS conditions: Ionization—ESI positive mode;
Capillary voltage—1.0 kV; ESI source temperature—120 ◦C; Desolvation gas (N2) flow—800 L/h;
Desolvation temperature—600 ◦C.
3. Results
Quantitative UPLC/MS/MS method is suitable for the determination of PMB and NAB739 in
mouse plasma in the concentration range from 0.02 to 16 µg/mL and in mouse urine in the concentration
range from 0.58 to 16 µg/mL. Performance of polymyxin analysis method and MRM parameters for
NAB739 and Polymyxin B are described in Tables 1 and 2.
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Table 1. Multiple reaction monitoring (MRM) parameters for NAB739 and Polymyxin B.
Compound MRM Transition Cone Voltage, V Collision Energy, eV
NAB739
359.66 > 425.19 30 8Exact mass 1076 Da
PMB *: 301.86 > 101.02 30 12
Polymyxin B1 402.12 > 101.02 30 15
Exact mass 1202 Da 602.50 > 101.02 30 30
298.36 > 101.02 30 10
Polymyxin B2 301.44 > 101.02 30 15
Exact mass 1188 Da 595.42 > 101.02 30 30
* Polymyxin B (PMB) measured as a sum of polymyxin B1 and polymyxin B2.
Table 2. Polymyxin analysis method performance.
Validation Parameter Performance Criteria
Obtained Value
NAB739 PMB
Plasma
Selectivity
Response for the analyte
in matrix blank ≤ 20% of
LOQ
2.3% 10%
Linearity R2 ≥ 0.985 R
2 0.9998 R2 0.9998
0.008–17.2 µg/mL 0.007–15.7 µg/mL
Limit of quantification Set at concentration level
where S/N ≥ 10
0.008 µg/mL 0.007 µg/mL
(S/N ≥ 40) (S/N ≥ 10))
Urine
Selectivity
Response for analyte in
matrix blank ≤ 20% of
LOQ
3.8% 10%
Linearity R2 ≥ 0.985 R
2 0.9996 R2 0.998
0.07–17.2 µg/mL 0.58–15.7 µg/mL
Limit of quantification Set at concentration level
where S/N ≥ 10
0.07 µg/mL 0.58 µg/mL
(S/N ≥ 20) (S/N ≥ 10))
3.1. Pharmacokinetic Profiles of NAB739 and PMB
The plasma concentrations of NAB739 and PMB were determined following single-dose and
four-times-repeated administration of compounds at doses of 0.25, 0.5, 1, 2, and 4 mg/kg. During the
administration of compounds, no adverse effects were observed at any of the tested doses.
After SC administration of NAB739 and PMB clear dose–response relationship for doses from
0.25 to 4 mg/kg was observed (Figure 2). Cmax values for both compounds and at all doses were
observed 30 min after the administration. The linearity of Cmax and a dose–response relationship was
slightly better for NAB739 than for PMB, correlation coefficients being 0.9987 and 0.975, respectively
(Figure 2C,D). After administration of NAB739 at a dose of 0.25 mg/kg its plasma concentrations
at all time points were above 0.5 µg/mL while after administration at a dose of 0.5 mg/kg plasma
concentrations exceeded 1 µg/mL.
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Figure 2. Concentrations of compounds in NMRI mice plasma after the first SC administration of
NAB739 (A) and PMB (B) at doses of 0.25–4mg/kg. Dose and Cmax relationship of NAB739 (C) and
PMB (D) at doses of 0.25–4 mg/kg. Data expressed as average ± SEM from four mice.
At all tested doses after both single and repeated dosing NAB739 reached higher plasma
concentra ions than PMB (Figure 3) indicating bett r bioavailability of NAB739. Cmax of NAB739
was up to 1.5-times igher after single (first) administra ion and up to two-times higher after the last
(fourth) administration when compared to PMB (Figure 3). Pl sma concentrations of PMB wer similar
after the first and the la t administration of the compound, while concentrations of NAB739 were up to
30% higher after the la dministra ion of the compound at doses of 2 and 4 mg/kg (Figure 3).
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Figure 3. of PK profiles in NMRI mice plasma after the first and the last SC admini ration
of NAB739 and PMB at doses of 4 (A), 2 (B), 1 (C), 0.5 (D), 0.25 (E) mg/kg. Data expressed as average ±
SEM from four mice.
3.2. Urinary Elimination of NAB739 and PMB
PMB was not detected in urine samples even when the compound was administered at a dose of
4 mg/kg (data not shown). NAB739 was found in all pooled (0–3 h) urine samples (Figure 4). After
administration of NAB739 at doses of 0.25–2 mg/kg urine concentrations of the compound on average
were 27% (5.1%–49%) higher after the last dose compared to concentration after the first dose (Figure 4).
The concentration of NAB739 in urine after single administration at a dose of 0.25 mg/kg was above 1
µg/mL while after administration of 0.5 mg/kg average urine concentration exceeded 2 µg/mL.
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4. Concentrations of NAB739 in NMRI mice urine afte the first and the last SC administration
t dose of 0.25–4 mg/kg. Data expressed as av rag ± SEM from four N RI mice.
As shown in Figure 5, the relative elimination of NAB739 by urine was similar for all doses.
On average, about 20% of the compound was eliminated by urine during 3 h after the first administration
of NAB739 at doses of 0.25–2 mg/kg. At a dose of 4 mg/kg about 35% of administered compound was
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eliminated by urine. After administration of the last dose, relative elimination of NAB739 was on
average 26% (5.1%–49%) higher than after the administration of the first dose of the compound.
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the amount of compound administrated in mice at particular dose. Data expressed as average ±SEM 
from four NMRI mice. 
4. Discussion 
We showed here that even though subcutaneous administration of NAB739 and PMB yielded 
similar plasma concentrations in mice, only NAB739 was eliminated into urine at reasonable 
quantities. After the fourth dose of PMB at a dose of 4 mg/kg, plasma level was above 6 µg/mL, but 
compound was not found in urine (detection limit, 0.6 µg/mL). In contrast, even at the doses of 0.25 
and 0.5 mg/kg, the concentration of NAB739 in urine was above 1 and 2 µg/mL, respectively. 
Higher doses yielded very high NAB739 concentrations in urine, thus after a dose of 4 mg/kg, the 
urinary concentrations of NAB739 were above 35 µg/mL. These differences explain our previous 
finding that NAB739 is much more efficacious than PMB for the treatment of murine E. coli 
pyelonephritis.  
The molecular mechanism behind our finding that NAB739 and NAB815, but not PMB, are 
excreted in urine, is not known. We have previously shown that compared to PMB, NAB 
polymyxin derivatives with three positive charges are much less bound to the brush border 
membrane of the kidney proximal tubule (PT) cells of rats [12]. This is likely since, in contrast to 
PMB with five positive charges, the NAB derivatives have only three positive charges and could, 
therefore, be less prone to interact with the negatively charged lipids mostly found in the cytosolic 
leaflet of the plasma membrane [13]. It may be possible that polymyxin B is reabsorbed (taken up) 
by the PT cells at a rate much higher than that for the less charged derivatives. 
Pyelonephritis is a complicated kidney-affecting urinary tract infection (cUTI) that can lead to 
septicemic blood stream infection, if not properly treated. Currently, PMB and colistin are used in 
humans. Colistin is administered intravenously as its bacteriologically inactive prodrug colistin 
methanesulfonate (CMS), also known as colistimethate [3]. Most of colistin is excreted into urine as 
its prodrug which is then partially decomposed in the bladder to the form of bacteriologically active 
free colistin [3]. For the therapy of lower urinary tract infections (i.e., bladder infections, cystitis), 
CMS might have some value, even though most cystitis patients receive oral antibiotics and are 
successfully treated in the primary care. However, the pharmacokinetics of CMS, including its 
hydrolysis to active drug, shows substantial interpatient variability and this makes the choice of the 
proper dose difficult [3]. PMB has superior pharmacokinetic characteristics over CMS for the 
treatment of infections where rapid achievement and maintenance of the desired plasma 
concentration is important [3]. According to the results of this study, treatment with NAB739 is far 
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4. Discussion
e showed here that even though subcutaneous administration of NAB739 and PMB yielded
similar plasma concentrations in mice, only NAB739 was eliminated into urine at reasonable quantities.
After the fourth dose of PMB at a dose of 4 mg/kg, plasma level was above 6 µg/mL, but compound
was not found in urine (detection limit, 0.6 µg/mL). In contrast, even at the doses of 0.25 and 0.5 mg/kg,
the concentration of NAB739 in urine was above 1 and 2 µg/mL, respectively. Higher doses yielded
very high NAB739 concentrations in urine, thus after a dose of 4 mg/kg, the urinary concentrations of
NAB739 were above 35 µg/mL. These differences explain our previous finding that NAB739 is much
more efficacious than PMB for the treatment of murine E. coli pyelonephritis.
The molecular mechanism behind our finding that NAB739 and NAB815, but not PMB, are
excreted in urine, is not known. We have previously shown that compared to PMB, NAB polymyxin
derivatives with three positive charges are much less bound to the brush border membrane of the
kidney proximal tubule (PT) cells of rats [12]. This is likely since, in contrast to PMB with five positive
charges, the NAB derivatives have only three positive charges and could, therefore, be less prone
to interact with the negatively charged lipids mostly found in the cytosolic leaflet of the plasma
membrane [13]. It may be possible that polymyxin B is reabsorbed (taken up) by the PT cells at a rate
much higher than that for the less charged derivatives.
Pyelonephritis is a complicated kidney-affecting urinary tract infection (cUTI) that can lead to
septicemic blood stream infection, if not properly treated. Currently, PMB and colistin are used
in humans. Colistin is administered intravenously as its bacteriologically inactive prodrug colistin
methanesulfonate (CMS), also known as colistimethate [3]. Most of colistin is excreted into urine as its
prodrug which is then partially decomposed in the bladder to the form of bacteriologically active free
colistin [3]. For the therapy of lower urinary tract infections (i.e., bladder infections, cystitis), CMS
might have some value, even though most cystitis patients receive oral antibiotics and are successfully
treated in the primary care. However, the pharmacokinetics of CMS, including its hydrolysis to active
drug, shows substantial interpatient variability and this makes the choice of the proper dose difficult [3].
PMB has superior pharmacokinetic characteristics over CMS for the treatment of infections where
rapid achievement and maintenance of the desired plasma concentration is important [3]. According
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to the results of this study, treatment with NAB739 is far superior since the compound can achieve
both rapid and stable plasma concentration profile and high concentrations in urine.
Our findings are highly significant because over 6.3 million patients are yearly hospitalized in
Europe, USA, and Japan due to cUTIs caused by E. coli and K. pneumoniae [14]. These two bacteria
cause 80% of all cUTIs treated in the hospitals. It is estimated that in the future, many patients will
likely be infected by extremely resistant strains. Therefore, novel polymyxins such as NAB739 and
NAB815 might be very useful for the efficient treatment of cUTIs. The only potential drawback is that
the use of polymyxins might be shadowed by already acquired resistance, even though this is still very
rare [15]. Additional benefit in the case of NAB739 treatment is the characteristic for polymyxins ability
to damage the outer membrane of polymyxin-resistant bacterial strains and, as a consequence, also the
ability to sensitize bacteria to various “partner antibiotics” [16]. Whether combination of a polymyxin
and a partner antibiotic will be effective in the case of cUTIs in the future, remains to be seen.
5. Conclusions
The comparison of urinary levels of NAB739 and polymyxin B shows that even though
subcutaneous administration of NAB739 and polymyxin B yield similar plasma concentrations
in mice, only NAB739 is excreted in the urine at sufficient antibacterial concentration. The low efficacy
of PMB against urinary tract infections demonstrated in previous studies is explained by the absence
of compound in the murine urine even after the treatment at a high dose. These results explain higher
efficacy of NAB739 than polymyxin B for the treatment of murine E. coli pyelonephritis.
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